Bąk E, Marcisz C, Borodzicz A, Sternal D, Krzemińska S. Comparison of health-related quality of life in patients with rheumatoid arthritis during conventional or conventional plus biological therapy in Poland. Patient Prefer Adherence. 2019;13:223–31. https://doi.org/10.2147/PPA.S189152.
PubMed
PubMed Central
Article
Google Scholar
Chancay M, Guendsechadze S, Blanco I. Types of pain and their psychosocial impact in women with rheumatoid arthritis. Women's Midlife Health. 2019;5:3.
PubMed
PubMed Central
Article
Google Scholar
“Rheumatoid arthritis in adults: management,” National Institute for Health and Care Excellence, July 2018. [Online]. Available: https://www.nice.org.uk/guidance/ng100/chapter/Recommendations#the-multidisciplinary-team. [Accessed 30 October 2019].
“Depression in adults with a chronic physical health problem: recognition and management Clinical guideline [CG91],” National Institute for Health and Care Excellence, October 2009. [Online]. Available: https://www.nice.org.uk/guidance/cg91. [Accessed 30 October 2019].
Zielinski M, Systrom D, Rose N. Fatigue, sleep, and autoimmune and related disorders. Front Immunol. 2019;10:1827. https://doi.org/10.3389/fimmu.2019.01827.
CAS
PubMed
PubMed Central
Article
Google Scholar
Turesson C, O’Fallon W, Crowson C, Gabriel S, Matteson E. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722–7. https://doi.org/10.1136/ard.62.8.722.
CAS
PubMed
PubMed Central
Article
Google Scholar
Humphreys J, Verstappen S, Hyrich K, Chipping J, Marshall T, Symmons D. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis. 2013;72(8):1315–20. https://doi.org/10.1136/annrheumdis-2012-201960.
PubMed
Article
Google Scholar
Smolen J, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–77.
PubMed
Article
Google Scholar
Song J, Song Y, Bae S, Cha H, Choe J, Choi S, Kim H, Kim J, Kim S, Lee C, Lee J, Lee S, Lee S, Lee S, Lee S, Park S, Park W, Shim S, Suh C, Yoo B, Yoo D, Yoo W. Treat-to-target strategy for asian patients with early rheumatoid arthritis: result of a multicenter trial in Korea. J Korean Med Sci. 2018;33(52):e346. https://doi.org/10.3346/jkms.2018.33.e346.
PubMed
PubMed Central
Article
Google Scholar
Damjanov N, Radunovic G, Prodanovic S, Vukovic V, Milic V, Simic Pasalic K, Jablanovic D, Seric S, Milutinovic S, Gavrilov N. Construct validity and reliability of ultrasound disease activity score in assessing joint inflammation in RA: comparison with DAS-28. Rheumatology (Oxford). 2012. https://doi.org/10.1093/rheumatology/ker255.
Article
Google Scholar
Scott I, Machin A, Mallen C, Hider S. The extra-articular impacts of rheumatoid arthritis: moving towards holistic care. BMC Rheumatol. 2018. https://doi.org/10.1186/s41927-018-0039-2.
PubMed
PubMed Central
Article
Google Scholar
“Living with Rheumatoid arthritis, NHS,” 28 August 2019. [Online]. Available: https://www.nhs.uk/conditions/rheumatoid-arthritis/living-with/. [Accessed 31 October 2019].
Covic T, Cumming S, Pallant J, Manolios N, Emery P, Conaghan P, Tennant A. Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the depression, anxiety and stress scale (DASS) and the hospital, anxiety and depression scale (HADS). BMC Psychiatry. 2012. https://doi.org/10.1186/1471-244X-12-6.
PubMed
PubMed Central
Article
Google Scholar
Morris A, Yelin E, Panopalis P, Julian L, Katz P. Long-term patterns of depression and associations with health and function in a panel study of rheumatoid arthritis. J Health Psychol. 2011;16(4):667–77. https://doi.org/10.1177/1359105310386635.
PubMed
PubMed Central
Article
Google Scholar
“Depression,” 22 March 2018. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/depression. [Accessed 30 October 2019].
Sturgeon J, Finan P, Zautra A. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. Nat Rev Rheumatol. 2016;12(9):532–42. https://doi.org/10.1038/nrrheum.2016.112.
PubMed
PubMed Central
Article
Google Scholar
Intriago M, Maldonado G, Cardenas J, Rios C. Quality of life in Ecuadorian patients with established rheumatoid arthritis. Open Access Rheumatol Res Rev. 2019;11:199–205. https://doi.org/10.2147/OARRR.S216975.
Article
Google Scholar
Twigg S, Hensor E, Emery P, Tennant A, Morgan A. Patient-reported outcomes as predictors of change in disease activity and disability in early rheumatoid arthritis: results from the Yorkshire early arthritis register. J Rheumatol. 2017;44(9):1331–400. https://doi.org/10.3899/jrheum.161214.
CAS
PubMed
PubMed Central
Article
Google Scholar
Straub R, Cutolo M. Psychoneuroimmunology—developments in stress research. Wien Med Wochenschr. 2018;168(3–4):76–84. https://doi.org/10.1007/s10354-017-0574-2.
PubMed
Article
Google Scholar
Rezaei F, Doost H, Molavi H. Depression and pain in patients with rheumatoid arthritis: mediating role of illness perception. Egypt Rheumatol. 2014;36(2):57–64. https://doi.org/10.1016/j.ejr.2013.12.007.
Article
Google Scholar
“Invisible Disease: Rheumatoid Arthritis and Chronic Fatigue Survey,” National Rheumatoid Arthritis Society, 16–22 June 2014. [Online]. Available: https://www.nras.org.uk/invisible-disease-rheumatoid-arthritis-and-chronic-fatigue-survey. [Accessed 30 October 2019].
Nikolaus S, Bode C, Taal E, Laar M. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res Am Coll Rheumatol. 2013;65(7):1128–46. https://doi.org/10.1002/acr.21949.
Article
Google Scholar
Peterson S, Piercy J, Blackburn S, Sullivan E, Karyekar C, Li N. The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis. BMC Rheumatol. 2019. https://doi.org/10.1186/s41927-019-0092-5.
PubMed
PubMed Central
Article
Google Scholar
Korte S, Straub R. Fatigue in inflammatory rheumatic disorders: pathophysiological mechanisms. Rheumatology (Oxford). 2019;58(5):v35–v50. https://doi.org/10.1093/rheumatology/kez413.
Article
Google Scholar
Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialog Clin Neurosci. 2002;4(1):7–20.
Google Scholar
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2013;52:2136–48. https://doi.org/10.1093/rheumatology/ket169.
PubMed
Article
Google Scholar
Cojocaru M, Cojocaru I, Silosi I, Vrabie C, Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. J Clin Med. 2010;5(4):286–91.
Google Scholar
Straub R, Dhabhar F, Bijlsma J, Cutolo M. How psychological sress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthritis Rheum. 2005;52:16–26. https://doi.org/10.1002/art.20747.
PubMed
Article
Google Scholar
DiMatteo M, Lepper H, Croghan T. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7. https://doi.org/10.1001/archinte.160.14.2101.
CAS
PubMed
Article
Google Scholar
Katz P, Yelin E. Activity loss and the onset of depressive symptoms: Do some activities matter more than others? Arthritis Rheum. 2001;44:1194–202. https://doi.org/10.1002/1529-0131(200105)44:5<1194:AID-ANR203>3.0.CO;2-6.
CAS
PubMed
Article
Google Scholar
Matcham F, Davies R, Hotopf M, Hyrich K, Norton S, Steer S, Galloway J. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018. https://doi.org/10.1093/rheumatology/kex528.
Article
Google Scholar
El Miedany Y (eds) Patient reported outcome measures in rheumatic diseases. Switzerland: Springer International Publishing ISBN 978–3–319–32851–5, 2016.
Siemons L, Klooster P, Vonkeman H, van de Laar M, Glas C. Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis. PLoS ONE. 2014;9(6):e100544. https://doi.org/10.1371/journal.pone.0100544.
CAS
PubMed
PubMed Central
Article
Google Scholar
Hansen I, Andreasen R, van Bui HM, Emamifar A. The reliability of disease activity score in 28 joints–c-reactive protein might be overestimated in a subgroup of rheumatoid arthritis patients, when the score is solely based on subjective parameters. J Clin Rheumatol. 2017;23(2):102–6. https://doi.org/10.1097/RHU.0000000000000469.
Article
Google Scholar
Slama I, Allali F, Lakhdar T, El Kabbaj S, Medrare L, Ngeuleu A, Rkain H, Hajjaj-Hassouni N. Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015. https://doi.org/10.1186/s12891-015-0718-8.
PubMed
PubMed Central
Article
Google Scholar
Morris A, Yelin E, Panopalis P, Julian L, Katz P. Long-term patterns of depression and associations with health and function in a panel study of rheumatoid arthritis. J Health Psychol. 2011;16:667–77. https://doi.org/10.1177/1359105310386635.
PubMed
PubMed Central
Article
Google Scholar
Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome. Trials. 2007. https://doi.org/10.1186/1745-6215-8-38.
PubMed
PubMed Central
Article
Google Scholar
Imran M, Saira Khan E, Ahmad N, Farman Raja S, Saeed M, Ijaz HI. Depression in rheumatoid arthritis and its relation to disease activity. Pak J Med Sci. 2015;31:393–7. https://doi.org/10.12669/pjms.312.6589.
PubMed
PubMed Central
Article
Google Scholar
Rathbun A, Reed G, Harrold L. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology. 2013;52:1785–94. https://doi.org/10.1093/rheumatology/kes356.
PubMed
Article
Google Scholar
Englbrecht M, Alten R, Aringer M, Baerwald C, Burkhardt H, Eby N, Flacke J, Fliedner G, Henkemeier U, Hofmann M, Kleinert S, Kneitz C, Krüger K, Pohl C, Schett G, Schmalzing M, Tausche A, Tony H, Wendler J. New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis—Implications from the prospective multicenter VADERA II study. PLoS ONE. 2019;14(5):e0217412. https://doi.org/10.1371/journal.pone.0217412.
CAS
PubMed
PubMed Central
Article
Google Scholar
Miwa Y, Ikari Y, Hosonuma M, Hatano M, Hayashi T, Kasama T, Sanada K. A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment. Eur J Rheumatol. 2018;5(2):111–4. https://doi.org/10.5152/eurjrheum.2018.17147.
PubMed
PubMed Central
Article
Google Scholar
Matcham F, Scott I, Rayner L, Hotopf M, Kingsley G, Norton S, Scott D, Steer S. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 2014; 44:123–130. www.elsevier.com/locate/semarthrit
Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk-Hustings Y, Dixon W, Hyrich K, Askling J, Gossec L. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016;18(1):251. https://doi.org/10.1186/s13075-016-1151-6.
PubMed
PubMed Central
Article
Google Scholar
Jagpal A, O’Beirne R, Morris M, et al. Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis? BMC Rheumatol. 2019;3:36. https://doi.org/10.1186/s41927-019-0087-2.
PubMed
PubMed Central
Article
Google Scholar
Hewlett S, Kirwan J, Bode C, Cramp F, Carmona L, Dures E, Englbrecht M, Fransen J, Greenwood R, Hagel S, van de Laar M, Molto A, Nicklin J, Petersson I, Redondo M, Schett G, Gossec L. The revised bristol rheumatoid arthritis fatigue measures and the rheumatoid arthritis impact of disease scale: validation in six countries. Rheumatology (Oxford). 2018;57(2):300–8. https://doi.org/10.1093/rheumatology/kex370.
Article
Google Scholar
Rongen-van Dartel S, Repping-Wuts H, van Hoogmoed D, Knoop H, Bleijenberg G, van Riel P, Fransen J. Relationship between objectively assessed physical activity and fatigue in patients with rheumatoid arthritis: inverse correlation of activity and fatigue. Arthritis Care Res (Hoboken). 2014;66(6):852–60. https://doi.org/10.1002/acr.22251.
CAS
Article
Google Scholar
Choy E. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(5):v51–v5555. https://doi.org/10.1093/rheumatology/kez389.
Article
Google Scholar
Gries K, Berry P, Harrington M, Crescioni M, Patel M, Rudell K, Safikhani S, Pease S, Vernon M. Literature review to assemble the evidence for response scales used in patient-reported outcome measures. J Patient Rep Outcomes. 2018. https://doi.org/10.1186/s41687-018-0056-3.
PubMed
PubMed Central
Article
Google Scholar
Brennan F, McInnes I. Evidence that cytokines play. J Clin Invest. 2008;118(11):3537–45. https://doi.org/10.1172/JCI36389.
CAS
PubMed
PubMed Central
Article
Google Scholar
Spies C, Straub R, Cutolo M, Buttgereit F. Circadian rhythms in rheumatology—a glucocorticoid perspective. Arthritis Res Ther. 2014;16(Suppl 2):S3. https://doi.org/10.1186/ar4687.
PubMed
PubMed Central
Article
Google Scholar
Furst D, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford). 2014;53(9):1560–9. https://doi.org/10.1093/rheumatology/ket414.
CAS
Article
Google Scholar
Agonia I, Couras J, Cunha A, Andrade A, Macedo J, Sousa-Pinto B. IL-17, IL-21 and IL-22 polymorphisms in rheumatoid arthritis: a systematic review and meta-analysis. Cytokine. 2019. https://doi.org/10.1016/j.cyto.2019.154813.
PubMed
Article
Google Scholar
Euesden J, Matcham F, Hotopf M, Steer S, Cope A, Lewis C, Scott I. The relationship between mental health, disease severity, and genetic risk for depression in early rheumatoid arthritis. Psychosom Med. 2017;79(6):638–45. https://doi.org/10.1097/PSY.0000000000000462.
PubMed
PubMed Central
Article
Google Scholar
Sattar N, McCarey D, Capell H, McInnes I. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–63. https://doi.org/10.1161/01.CIR.0000099844.31524.05.
PubMed
Article
Google Scholar
Silman A, Pearson J. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(3):S265–S272272. https://doi.org/10.1186/ar578.
PubMed
PubMed Central
Article
Google Scholar
Lee J, Kim H, Lee D, Son C. Oxidative stress is a convincing contributor to idiopathic chronic fatigue. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-31270-3.
PubMed
PubMed Central
Article
Google Scholar
Dantzer R. Cytokine, sickness behavior, and depression. Neurol Clin. 2006;24(3):441–60. https://doi.org/10.1016/j.ncl.2006.03.003.
PubMed
PubMed Central
Article
Google Scholar
GS Ebrahim Haroon. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology. 2017;42(1):193–21515. https://doi.org/10.1038/npp.2016.199.
CAS
Article
Google Scholar
Drake C, Boutin H, Jones M, et al. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun. 2011;25(6):1113–22. https://doi.org/10.1016/j.bbi.2011.02.008.
CAS
PubMed
PubMed Central
Article
Google Scholar
Crotti C, Biggioggero M, Becciolini A, Favalli E. Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Relat Outcome Meas. 2018;9:275–84. https://doi.org/10.2147/PROM.S147286.
PubMed
PubMed Central
Article
Google Scholar
Cutolo M. NEIRD: a neuroendocrine immune network beyond the rheumatic diseases. Ann N Y Acad Sci. 2014. https://doi.org/10.1111/nyas.12439.
PubMed
Article
Google Scholar
Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA. Ann Rheum Dis. 2003;62:593–6. https://doi.org/10.1136/ard.62.7.593.
CAS
PubMed
PubMed Central
Article
Google Scholar
Miller A. Five things to know about inflammation and depression. Psychiatric Times. 2018;35(4):2018.
Google Scholar
Maes M, Van Bockstaele D, Gastel A, Song C, Schotte C, Neels H, DeMeester I, Scharpe S, Janca A. The effects of psychological stress on leukocyte subset distribution in humans: evidence of immune activation. Neuropsychobiology. 1999;39(1):1–9. https://doi.org/10.1159/000026552.
CAS
PubMed
Article
Google Scholar
Tsuboi H, Minamida Y, Tsujiguchi H, Matsunaga M, Hara A, Nakamura H, Tsuboi H, Sakakibara H. Elevated levels of serum IL-17A in community-dwelling women with higher depressive symptoms. Behav Sci (Basel). 2018;8(11):102. https://doi.org/10.3390/bs8110102.
Article
Google Scholar
Felger J, Lotrich F. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229. https://doi.org/10.1016/j.neuroscience.2013.04.060.
CAS
PubMed
PubMed Central
Article
Google Scholar
Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Björkqvist M, Träskman-Bendz L, Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287–92. https://doi.org/10.1016/j.biopsych.2009.01.030.
CAS
PubMed
Article
Google Scholar
Yoshimura R, Kishi T, Iwata N. Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites. Neuropsychiatr Dis Treat. 2019;15:2655–61. https://doi.org/10.2147/NDT.S195379.
CAS
PubMed
PubMed Central
Article
Google Scholar
Pariante CM. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur Neuropsychopharmacol. 2017;27(6):554–9. https://doi.org/10.1016/j.euroneuro.2017.04.001.
CAS
PubMed
Article
Google Scholar
Meade T, Manolios N, Cumming S, Conaghan P, Katz A. Cognitive impairment in rheumatoid arthritis: a systematic review. Arthritis Care Res Am College Rheumatol. 2018;70(1):39–52. https://doi.org/10.1002/acr.23243.
Article
Google Scholar
Bartolini M, Candela M, Brugni M, Catena L, Mari F, Pomponio G, Provinciali L, Danieli G. Are behaviour and motor performances of rheumatoid arthritis patients influenced by subclinical cognitive impairments? A clinical and neuroimaging study. Clin Exp Rheumatol. 2002;20(4):491–7. https://doi.org/10.1038/nrrheum.2016.112.
CAS
PubMed
Article
Google Scholar
Shin S, Katz P, Wallhagen M, Julian L. Cognitive Impairment in Persons With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2012;64(8):1144–50. https://doi.org/10.1002/acr.21683.
Article
Google Scholar
Oláh C, Kardos Z, Andrejkovics M, Szarka E, Hodosi K, Domján A, Sepsi M, Sas A, Kostyál L, Fazekas K, Flórián A, Lukács K, Miksi A, Baráth Z, Kerekes G, Péntek M, Valikovics A, Tamási L, Bereczki D, Szekanecz Z. Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety. Rheumatol Int. 2019. https://doi.org/10.1007/s00296-019-04449-8.
PubMed
Article
Google Scholar
Said F, Betoni T, Magalhaes V, Nisihara R, Skare T. Rheumatoid arthritis and cognition dysfunction: lack of association with cumulative glucocorticoid use. Immunopharmacol Immunotoxicol. 2019. https://doi.org/10.1080/08923973.2019.1679170.
PubMed
Article
Google Scholar
Miwa Y, Isojima S, Saito M, Ikari Y, Kobuna M, Hayashi T, Takahashi R, Kasama T, Hosaka M, Sanada K. Comparative study of infliximab therapy and methotrexate monotherapy to improve the clinical effect in rheumatoid arthritis patients. Intern Med. 2016;55(18):2581–5. https://doi.org/10.2169/internalmedicine.55.6872.
CAS
PubMed
Article
Google Scholar
Yayikci Y, Karadag A. Effects of conventional and biological drugs used for the treatment of rheumatoid arthritis on the quality of life and depression. Euras J Med. 2019;51(1):12–6. https://doi.org/10.5152/eurasianjmed.2018.18018.
Article
Google Scholar
Bai S, Guo W, Feng Y, Deng H, Li G, Nie H, Guo G, Yu H, Ma Y, Wang J, Chen S, Jing J, Yang J, Tang Y, Tang Z. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2019. https://doi.org/10.1136/jnnp-2019-320912.
PubMed
Article
Google Scholar
Molero P, Ruiz-Estigarribia L, Lahortiga-Ramos F, Sánchez-Villegas A, Bes-Rastrollo M, Escobar-González M, Martínez-González M, Fernández-Montero A. Use of non-steroidal anti-inflammatory drugs, aspirin and the risk of depression: the “Seguimiento Universidad de Navarra (SUN)” cohort. J Affect Disord. 2019;247:161–7. https://doi.org/10.1016/j.jad.2019.01.020.
CAS
PubMed
Article
Google Scholar
Song Q, Fan C, Wang P, Li Y, Yang M, Yu S. Hippocampal CA1 βCaMKII mediates neuroinflammatory responses via COX-2/PGE2 signaling pathways in depression. J Neuroinflammation. 2018;15(1):338. https://doi.org/10.1186/s12974-018-1377-0.
CAS
PubMed
PubMed Central
Article
Google Scholar
Bauer I, Green C, Colpo G, Teixeira A, Selvaraj S, Durkin K, Zunta-Soares G, Soares J. A double-blind, randomized, placebo-controlled study of aspirin and n-acetylcysteine as adjunctive treatments for bipolar depression. J Clin Psychiatry. 2018. https://doi.org/10.4088/JCP.18m12200.
PubMed
PubMed Central
Article
Google Scholar
Qin D, Li Z, Li Z, Wang L, Hu Z, Lü L, Wang Z, Liu Y, Yin Y, Li Z, Hu X. Chronic glucocorticoid exposure induces depression-like phenotype in Rhesus macaque (Macaca Mulatta). Front Neurosci. 2019;13:188. https://doi.org/10.3389/fnins.2019.00188.
PubMed
PubMed Central
Article
Google Scholar
Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63–77. https://doi.org/10.1016/j.neuropharm.2011.07.036.
CAS
PubMed
Article
Google Scholar
Zhang W, Egashira N, Masuda S. Recent topics on the mechanisms of immunosuppressive therapy-related neurotoxicities. Int J Mol Sci. 2019;20(13):E3210. https://doi.org/10.3390/ijms20133210.
CAS
PubMed
Article
Google Scholar
Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas A, Pinho de Oliveira C, Nardi A, Silva A. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry 2013;54(8):1185–9. https://doi.org/10.1016/j.comppsych.2013.05.010.
Strand V, Scott D, Emery P, Kalden J, Smolen J, Cannon G, Tugwell P, Crawford B, Gro LRAI. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol. 2005;32(4):590–601.
CAS
PubMed
Google Scholar
Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment e. Arthritis Rheum. 2000;43(3):506–14.
CAS
PubMed
Article
Google Scholar
Wen J, Maxwell R, Wolf A, Spira M, Gulinello M, Cole P. Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model. Neuropharmacology. 2018;139:76–84. https://doi.org/10.1016/j.neuropharm.2018.07.007.
CAS
PubMed
PubMed Central
Article
Google Scholar
Tłustochowicz M, Kisiel B, Tłustochowicz W. “Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in therapeutic program: a retrospective analysis of data from the PLUS study. Adv Clin Exp Med. 2019. https://doi.org/10.17219/acem/104548.
PubMed
Article
Google Scholar
Zhou A, Lee Y, Salvadore G, Hsu B, Fonseka T, Kennedy S, McIntyre R. Sirukumab: a potential treatment for mood disorders? Adv Ther. 2017;34(1):78–90. https://doi.org/10.1007/s12325-016-0455-x.
CAS
PubMed
Article
Google Scholar
Corominas H, Alegre C, Narváez J, Fernández-Cid C, Torrente-Segarra V, Gómez M, Pan F, Morlà R, Martínez F, Gómez-Centeno A, Ares L, Molina R, González-Albo S, Dalmau-Carolà J, Pérez-García C, Álvarez C, Ercole L, Terrancle M. Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study. Medicine (Baltimore). 2019;98(26):e15947. https://doi.org/10.1097/MD.0000000000015947.
Article
Google Scholar
Biggioggero M, Crotti C, Becciolini A, Favalli E. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2018;13:57–70. https://doi.org/10.2147/DDDT.S150580.
PubMed
PubMed Central
Article
Google Scholar
Bekhbat M, Chu K, Le N, Woolwine B, Haroon E, Miller A, Felger J. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology. 2018;98:222–9. https://doi.org/10.1016/j.psyneuen.2018.09.004.
CAS
PubMed
PubMed Central
Article
Google Scholar
Mason A, Holmes C, Edwards C. Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments? Autoimmun Rev. 2018;17:919–25.
CAS
PubMed
Article
Google Scholar
Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford). 2012;51(1):60–8. https://doi.org/10.1093/rheumatology/ker162.
CAS
Article
Google Scholar
Kremer J, Schiff M, Muram D, Zhong J, Alam J, Genovese M. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open. 2018. https://doi.org/10.1136/rmdopen-2017-000581.
PubMed
PubMed Central
Article
Google Scholar
Strand V, Mysler E, Moots R, Wallenstein G, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen J, Fleischmann R. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5(2):e001040. https://doi.org/10.1136/rmdopen-2019-001040.
PubMed
PubMed Central
Article
Google Scholar
Strand V, Lee E, Fleischmann R, Alten R, Koncz T, Zwillich S, Gruben D, Krishnaswami S, Wallenstein G. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016;2(2):e000308. https://doi.org/10.1136/rmdopen-2016-000308.
PubMed
PubMed Central
Article
Google Scholar
Strand V, Pope J, Tundia N, Friedman A, Camp H, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21:272. https://doi.org/10.1186/s13075-019-2037-1.
CAS
PubMed
PubMed Central
Article
Google Scholar
Baker K, Isaacs J, Thompson B. "Living a normal life": a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis. BMC Rheumatol. 2019. https://doi.org/10.1186/s41927-019-0070-y.
PubMed
PubMed Central
Article
Google Scholar